DnB Asset Management
IMVT icon

DnB Asset Management’s Immunovant IMVT Stock Holding History

DnB Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,109
Closed -$460K – 1246
2025
Q4 		$460K Buy
18,109
+5,701
+46% +$127K ﹤0.01% 680
2025
Q3 		$200K Sell
12,408
-496
-4% -$8.03K ﹤0.01% 718
2025
Q2 		$206K Sell
12,904
-1,452
-10% -$22K ﹤0.01% 699
2025
Q1 		$245K Buy
14,356
+3,935
+38% +$82.3K ﹤0.01% 701
2024
Q4 		$258K Sell
10,421
-66
-0.6% -$1.87K ﹤0.01% 697
2024
Q3 		$299K Buy
10,487
+197
+2% +$5.81K ﹤0.01% 680
2024
Q2 		$271K Buy
10,290
+958
+10% +$27.2K ﹤0.01% 678
2024
Q1 		$302K Buy
+9,332
New +$340K ﹤0.01% 677

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

DnB Asset Management's IMVT Position: Q1 2026 in Review

DnB Asset Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 18,109 shares — an estimated $460K sold.

DnB Asset Management first reported a position in IMVT in Q1 2024 and held it in 8 quarters. The position peaked at $460K in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • DnB Asset Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • DnB Asset Management sold 18,109 Immunovant shares in Q1 2026, an estimated $460K.
  • DnB Asset Management first reported a position in Immunovant in Q1 2024 and held it in 8 quarters.
  • DnB Asset Management's Immunovant position peaked at $460K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.